| Molecule | Cat. No. | Product Name | 種 | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| HLA-A*0201 & B2M & EBV LMP1 (YLLEMLWRL) | Biotinylated Human HLA-A*02:01&B2M&EBV LMP1 (YLLEMLWRL) Complex Protein (Monomer, MALS verified) |  Human | HEK293 | MALSSDS-PAGE | $125.00 25ug | |||
| HLA-A*0201 & B2M & EBV LMP1 (YLLEMLWRL) | PE-Labeled Human HLA-A*02:01&B2M&EBV LMP1 (YLLEMLWRL) Tetramer Protein | Human | HEK293 | $410.00 25ug |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| NGM-313 | NGM-313; MK-3655 | Phase 2 Clinical | Ngm Biopharmaceuticals Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Hepatitis; Obesity | 詳細 |
| Fazpilodemab | RG-7992; BFKB-8488A; RO-7040551 | Phase 1 Clinical | Genentech Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Insulin Resistance | 詳細 |
| B-1344 | B-1344 | Phase 1 Clinical | Tasly Biomedical Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2 | 詳細 |
